Therapeutic management of bacterial meningitis in children: A systematic review and comparison of published guidelines from a European perspective

Journal of Chemotherapy

Volumn 22, Issue 4, 2010, Pages 226-237

  De Gaudio, M ^a   Chiappini, E ^a   Galli, L ^a   De Martino, Maurizio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antibiotic resistance rates; Antimicrobial therapy; Bacterial meningitis; Children; Dexamethasone

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; AMPICILLIN; AZTREONAM; BERLOCOMBIN; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; CHLORAMPHENICOL; DEXAMETHASONE; GENTAMICIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PENICILLIN G; QUINOLONE DERIVATIVE; RIFAMPICIN; VANCOMYCIN;

ABDOMINAL DISCOMFORT; ANTIBIOTIC RESISTANCE; APNEA; BACTERIAL MENINGITIS; CEREBROSPINAL FLUID; CHILD; CHOLELITHIASIS; CLINICAL TRIAL; COMA; CONSCIOUSNESS DISORDER; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; EPIDEMIC MENINGITIS; EXFOLIATIVE DERMATITIS; FEVER; GROUP B STREPTOCOCCAL MENINGITIS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS MENINGITIS; HEARING LOSS; HUMAN; INTERSTITIAL NEPHRITIS; KERNICTERUS; KIDNEY FAILURE; LISTERIA MONOCYTOGENES; LISTERIOSIS; LUMBAR PUNCTURE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NAUSEA; NEISSERIA MENINGITIDIS; NEPHROLITHIASIS; NEPHROTOXICITY; NEUROIMAGING; NEUROSURGERY; NEUTROPENIA; NONHUMAN; OTOTOXICITY; PANCREATITIS; PHLEBITIS; PNEUMOCOCCAL MENINGITIS; PROTHROMBIN TIME; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; REVIEW; SEIZURE; SHOCK; SIDE EFFECT; STEVENS JOHNSON SYNDROME; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; TOXIC EPIDERMAL NECROLYSIS; VASCULITIC RASH; VESTIBULAR DISORDER; VOMITING;

EID: 78650243509     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.4.226     Document Type: Review

References (42)

1. Chaudhuri A, Martinez-Martin PM, Kennedy PG, Andrew Seaton R, Portegies P, Bojar M, et al. EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS task force on acute bacterial meningitis in older children and adults. Eur J Neurology 2008;15:649-659. (Pubitemid 351814425)
2. Infectious Diseases and Immunization Committee, Canadian Paediatric Society. Therapy of suspected bacterial meningitis in Canadian children six weeks of age and older. Paediatr Child Health 2008;13:309-317.
3. Tunkel AR, Hartman BJ, Sheldon LK, Kaufman BA, Roos KL, Sheld WM, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267-1284. (Pubitemid 39458512)
4. Fitch MT, Abrahamian FM, Moran GJ, Talan DA. Emergency department management of meningitis and encephalitis. Infect Dis Clin N Am 2008; 22:33-52. (Pubitemid 351273538)
5. Bettinger JA, Scheifele DW, Halperin SA, Kellner JD, Tyrrel G. Canadian Paediatric Society Immunization Monitoring Program Active. Invasive pneumococcal infections in Canadian children, 1998-2003 amplications for new vaccination programs. Can J Public Health 2007; 98:111-115.
6. American Academy of Pediatrics. 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village. 2006: 288-522.
7. Sudarsanam T, Rupali P, Tharyan P, Abraham OC, Thomas K. Pre-admission antibiotics for suspected cases of meningococcal disease. Cochrane Database Syst Rev 2008; 23:CD005437.
8. Prasad K, Kumar A, Gupta PK, Singhal T. Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis. Cochrane Database Syst Rev 2007; 17:CD001832.
9. van de Beek D, de Gans J, McIntyre P, Prasad K. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2007; 24:CD004405.
10. Kim KS. Acute bacterial meningitis in infants and children. Lancet Infect Dis 2010;10:32-42.
11. Scholz H, Hofmann T, Noack R, Edward DJ, Stoeckel K. Prospective comparison of ceftriaxone and cefotaxime for the short-term treatment of bacterial meningitis in children. Chemotherapy 1998;44:142-147. (Pubitemid 28105428)
12. Goldwater PN. Cefotaxime and ceftriaxone cerebrospinal fluid levels during treatment of bacterial meningitis in children. Int J Antimicrob Agents 2005;26:408-411. (Pubitemid 41483472)
13. Morikawa Y, Kitazato T, Morita T, Mizunaga S, Mitsuyama J. Clinica significance of cerebrospinal fluid inhibitory titers of antibiotics, based on pharmacokinetics/ pharmacodynamic parameters, in the treatment of bacterial meningitis. J Infect Chemother 2009;15:233-238.
14. Craig WA. Pharmacokinetics/ pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10.
15. Vardakas KZ, Matthaiou DK, Falagas ME. Adjunctive dexamethasone therapy for bacterial meningitis in adults: a meta-analysis of randomized controlled trials. Eur J Neurol 2009; 16:662 673.
16. van de Beek D, Farrar JJ, de Gans J, Thi Hoang Mai N, Molyneux EM, Peltola H. Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data. Lancet Neurol 2010;9:254-263.
17. Feigin RD. Use of corticosteroids in bacterial meningitis. Pediatr Infect Dis J 2004; 23:355-357.
18. Ricard J-D, Wolff M, Lacherade J-C, Mourvillier B, Hidri N, Barnaud G, et al. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicente observational study. Clin Infect Dis 2007; 44:250-255.
19. Deghmane AE, Alonso JM, Taha MK. Emerging drugs for acute bacterial meningitis. Expert Opin. Emerging Drugs 2009; 14:381-393.
20. Dessi A, Puddu M, Testa M, Marcialis M.A., Pintus M.C., Fanos V. Serratia marcescens infections and outbreaks in neonatal intensive unites. J Chemother 2009;21:493-499.
21. Hirooka TM, Fontes RB, Dinez EM, Pintos FC, Matushita H. Cerebral abscess caused by Serratia marcescens in a premature neonate. Arq Neuropsiquiatr 2007;65:1018-1021.
22. The British National Formulary for Children 2009 [http://www.bnfc.org].
23. Bradley JS, Wassel RT, Lee L, Nambiar S. Intravenous ceftriaxone in the neonate: assessing the risk of cardiopulmonary adverse events. Pediatrics 2009;123:609-613.
24. Mace SE. Acute bacterial meningitis. Emerg Med Clin North Am 2008;26:281-317.
25. Chavez-Bueno S, McCracken GH Jr. Bacterial meningitis in children. Pediatr Clin North Am 2005;52:795-810.
26. Chang YC, Huang CC, Wang ST, Chio CC. Risk factor of complications requiring neurosurgical intervention in infants with bacterial meningitis. Pediatr Neurol 1997;17:144-149.
27. van de Beek D, Campeau NG, Wijdicks EF. The clinical challenge of recognizing infratentorial empiema. Neurology 2007;69:477-481. (Pubitemid 47450283)
28. Tzanakaki G, Mastrantonio P. Aetiology of bacterial meningitis and resistance to antibiotics of causative pathogens in Europe and in the Mediterranean region. Int J AnLimicrob Agents 2007; 29:621-629. (Pubitemid 46710366)
29. Vazquez JA, Enriquez R, Abad R, Alcala B, Salcedo C, Areaza R. Antibiotic resistant meningococci in Europe: any need to act? FEMS Microbiol Rev 2007; 31:64-70.
30. The European Antimicrobial Resistance Surveillance System (EARSS). Annual Report 2007 [http://www.rivm.nl/earss/images/EARSS%202007-FINAL-tcm61.]
31. Grebe T, Hakenbeck R. Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of beta-lactam antibiotics. Antimicrob Agents Chemother 1996; 40:829-834. (Pubitemid 126501280)
32. Scriver SR, Walmsley SL, Kau CL, Hoban DJ, Brunton J, McGeer A, et al. Determination of antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae and characterization of their beta-lactamases. Antimicrob Agents Chemother 1994; 38: 1678-1680. (Pubitemid 24203593)
33. Blosser-Middleton R., Sahm DF, Thornsberry C, Jones ME, Hogan PA, Critchley IA, et al. Antimicrobial susceptibility of 840 clinical isolates of Haemophilus influenzae collected in four European countries in 2000-2001.Clin Microbiol Infect 2003; 9:431-436.
34. Campos J, Hernando M, Roman F, Perez-Vazquez M, Aracil B, Oteo J, et al. Analysis of invasive Haemophilus influenzae infections after extensive vaccination against H. influenzae type b. J Clin Microbiol 2004; 42:524-529. (Pubitemid 38222623)
35. Rajanca P, Canica M, the Multicenter Study Group. Emergence of nonencapsulated and encapsulated non-h-type invasive Haemophilus influenzae isolates in Portugal (1989-2001). J Clin Microhiol 2004;42:807-810.
36. Cerquetti M, Cardines R, Giufrè M, Sofia T, D'Ambrosio F, Mastrantonio P, et al. Antimicrobial susceptibility of Hemophilus influenzae strains isolated from invasive disease in Italy. J Antimicrob Chemother 2004; 54:1139-1143. (Pubitemid 40136756)
37. Hof H. Therapeutic options. FEMS Immunol Med Microbiol 2003; 35:203-205.
38. Hof H. An update on the medical management of listeriosis. Expert Opin Pharmacother 2004; 5:1727-1735.
39. Mitjà O, Pigrau C, Ruiz I, Vidal X, Almirante B, Planes A-M, et al. Predictors of mortality and impact of aminoglycosides on outcome in listeriosis in a retrospective cohort study. J Antimicrob Chemother 2009; 64: 416-423.
40. Poyart C, Reglier-Poupet H, Tazi A, Billoet A, Dmytruk M, Bidet P, et al. Invasive group B streptococcal infections in infants, France. Emerg Infect Dis 2008; 14:1647-1649.
41. Trijbels-Smeulders MA, Kimpen JL, Kollée LA, Bakkers J, Melchers W, Spanjaard L, et al. Serotypes, genotypes, and antibiotic susceptibility profiles of group B streptococci causing neonatal sepsis and meningitis before and after introduction of antibiotic prophylaxis. Pediatr Infect Dis J 2006; 25:945-948. (Pubitemid 44510594)
42. Weisner AM, Johnson AP, Lamagni TL, Arnold E, Warner M, Heath PT, et al. Characterization of group B streptococci recovered from infants with invasive disease in England and Wales. Clin Infect Dis 2004; 38:1209-1211.